CCWM
BIB icon

Cassaday & Co Wealth Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Cassaday & Co Wealth Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,499
Closed -$228K – 319
2024
Q4 		$228K Hold
4,499
– – 0.01% 294
2024
Q3 		$287K Hold
4,499
– – 0.01% 249
2024
Q2 		$267K Hold
4,499
– – 0.01% 241
2024
Q1 		$259K Hold
4,499
– – 0.01% 249
2023
Q4 		$257K Sell
4,499
-29,415
-87% -$1.38M 0.01% 234
2023
Q3 		$1.63M Hold
33,914
– – 0.07% 60
2023
Q2 		$1.76M Buy
33,914
+80
+0.2% +$4.41K 0.07% 60
2023
Q1 		$1.83M Buy
33,834
+521
+2% +$29.4K 0.08% 55
2022
Q4 		$1.92M Buy
+33,313
New +$1.88M 0.09% 53

Other funds holding BIB

IMC Chicago
IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
WWM
Westwood Wealth Management Los Angeles, California $255M AUM 54.97% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
PSFG
Park Square Financial Group Roswell, Georgia $13.2M AUM 23.63% 1-Year Est. Return

Cassaday & Co Wealth Management's BIB Position: Q1 2025 in Review

Cassaday & Co Wealth Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2025, closing a stake of 4,499 shares — an estimated $228K sold.

Cassaday & Co Wealth Management first reported a position in BIB in Q4 2022 and held it in 9 quarters. The position peaked at $1.92M in Q4 2022. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2025.

  • Cassaday & Co Wealth Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2025 after selling out during the quarter.
  • Cassaday & Co Wealth Management sold 4,499 ProShares Ultra NASDAQ Biotechnology shares in Q1 2025, an estimated $228K.
  • Cassaday & Co Wealth Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2022 and held it in 9 quarters.
  • Cassaday & Co Wealth Management's ProShares Ultra NASDAQ Biotechnology position peaked at $1.92M in Q4 2022.
  • 23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2025.

Based on Cassaday & Co Wealth Management's 13F filing for Q1 2025, filed 5 May 2025.